The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Applied Therapeutics, Inc.

Investors’ Rights Alert

Los Angeles, CA / Accesswire / January 6, 2025

The Schall Law Firm, a national shareholder rights litigation firm, recently reminded investors of a class action lawsuit against Applied Therapeutics, Inc. This lawsuit alleges violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated by the U.S. Securities and Exchange Commission. Investors who purchased the Company’s securities between January 3, 2024 and December 2, 2024 (the “Class Period”) are urged to contact the firm before February 18, 2025.

Applied Therapeutics is facing allegations of misleading investors about the safety and efficacy of its products during the Class Period. This has resulted in significant financial losses for shareholders who relied on the Company’s false and misleading statements.

The Schall Law Firm is known for its dedication to protecting shareholder rights and fighting against corporate misconduct. They are committed to helping investors who have been harmed by securities fraud and misconduct.

If you purchased Applied Therapeutics securities during the Class Period and have suffered financial losses, it is important to reach out to the Schall Law Firm before the upcoming deadline. They can provide you with legal guidance and support to help you recover your losses.

Impact on Individuals

As an investor who purchased Applied Therapeutics securities during the Class Period, you may be entitled to compensation if the allegations of securities fraud are proven true. By contacting the Schall Law Firm before the deadline, you can take the necessary steps to protect your rights and seek justice for the losses you have incurred.

Global Implications

The outcome of this class action lawsuit against Applied Therapeutics could have far-reaching consequences for investors and the financial markets worldwide. If the Company is found to have engaged in securities fraud, it may lead to increased scrutiny on other pharmaceutical companies and potentially result in regulatory changes to prevent similar misconduct in the future.

Conclusion

Investors who purchased Applied Therapeutics securities during the Class Period should act quickly to protect their rights and pursue compensation for their losses. By contacting the Schall Law Firm before the deadline, you can ensure that your voice is heard and that justice is served in the face of corporate misconduct.